Cargando…

Clinical implications of low estimated protein intake in patients with heart failure

BACKGROUND: A higher protein intake has been associated with a higher muscle mass and lower mortality rates in the general population, but data about protein intake and survival in patients with heart failure (HF) are lacking. METHODS: We studied the prevalence, predictors, and clinical outcome of e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Streng, Koen W., Hillege, Hans L., ter Maaten, Jozine M., van Veldhuisen, Dirk J., Dickstein, Kenneth, Ng, Leong L., Samani, Nilesh J., Metra, Marco, Ponikowski, Piotr, Cleland, John G., Anker, Stefan D., Romaine, Simon P.R., Damman, Kevin, van der Meer, Peter, Lang, Chim C., Voors, Adriaan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178387/ https://www.ncbi.nlm.nih.gov/pubmed/35426256 http://dx.doi.org/10.1002/jcsm.12973

Ejemplares similares

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction
por: ter Maaten, Jozine M., et al.
Publicado: (2020)

The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure
por: Pandhi, Paloma, et al.
Publicado: (2021)

A network analysis to identify pathophysiological pathways distinguishing ischaemic from non‐ischaemic heart failure
por: Sama, Iziah E., et al.
Publicado: (2020)

Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin–angiotensin–aldosterone system in patients with heart failure
por: Boorsma, Eva M., et al.
Publicado: (2021)

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors
por: Sama, Iziah E, et al.
Publicado: (2020)

Albuminuria as a marker of systemic congestion in patients with heart failure
por: Boorsma, Eva M, et al.
Publicado: (2022)

Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure
por: Kobayashi, Masatake, et al.
Publicado: (2020)

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF
por: Pagnesi, Matteo, et al.
Publicado: (2021)

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2019)

Correction to: The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure
por: Santema, Bernadet T., et al.
Publicado: (2020)

Pathophysiological pathways in patients with heart failure and atrial fibrillation( )
por: Santema, Bernadet T, et al.
Publicado: (2021)

Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure
por: Pagnesi, Matteo, et al.
Publicado: (2022)

Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
por: Inciardi, Riccardo M., et al.
Publicado: (2022)

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation
por: Mordi, Ify R., et al.
Publicado: (2019)

A combined clinical and biomarker approach to predict diuretic response in acute heart failure
por: ter Maaten, Jozine M., et al.
Publicado: (2015)

Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure
por: Ceelen, Daan, et al.
Publicado: (2022)

Selenium and outcome in heart failure
por: Bomer, Nils, et al.
Publicado: (2019)

Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF
por: Markousis-Mavrogenis, George, et al.
Publicado: (2021)

Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) trial
por: ter Maaten, Jozine M., et al.
Publicado: (2022)

The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach
por: Hoes, Martijn F., et al.
Publicado: (2019)

Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence
por: Bracun, Valentina, et al.
Publicado: (2022)

Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? Reply
por: Damman, Kevin, et al.
Publicado: (2020)

Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure
por: Cao, Thong Huy, et al.
Publicado: (2018)

Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets
por: Cao, Thong H., et al.
Publicado: (2019)

Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction
por: Woolley, Rebecca J., et al.
Publicado: (2021)

Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial
por: ter Maaten, Jozine M., et al.
Publicado: (2023)

Genetic risk and atrial fibrillation in patients with heart failure
por: Kloosterman, Mariëlle, et al.
Publicado: (2020)

Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use
por: van der Wal, Haye H, et al.
Publicado: (2019)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment
por: Nauta, Jan F., et al.
Publicado: (2019)

What is the added value of the waist‐to‐hip ratio on top of the BIOSTAT risk prediction model in patients with heart failure? Reply
por: Streng, Koen W., et al.
Publicado: (2018)

Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
por: Boorsma, Eva M., et al.
Publicado: (2020)

Current and novel renal biomarkers in heart failure
por: Damman, Kevin, et al.
Publicado: (2011)

Clinical importance of urinary sodium excretion in acute heart failure
por: Damman, Kevin, et al.
Publicado: (2020)

Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction
por: Curran, Fraser M., et al.
Publicado: (2021)

Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure
por: Nath, Mintu, et al.
Publicado: (2022)

Impaired High‐Density Lipoprotein Function in Patients With Heart Failure
por: Emmens, Johanna E., et al.
Publicado: (2021)

Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure
por: Markousis-Mavrogenis, George, et al.
Publicado: (2023)

Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study
por: Alnuwaysir, Ridha I.S., et al.
Publicado: (2021)

Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure
por: Damman, Kevin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u51icljvh4fmeg7gvr3640828t